| 05.04.17 | Novartis and Roche back new gene therapy hopeful; Novartis says yes to Conatus' NASH drug

Laden...

7 jaren geleden

Html
Tekst

To view this email as a web page, click here

This week's sponsor is Premier Research.
	Discovering the Great Potential of Immuno-Oncology Drugs Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best.

Today's Rundown

Swiss majors Roche and Novartis back gene therapy upstart

Novartis adds to NASH pipeline, activating license for Conatus' emricasan

Poxel shares jump 40% after diabetes trial hits primary goal

[Sponsored] Mitotech’s SkQ1 targets mtROS, and a long list of age-related diseases

I-O startup Gritstone lures Rousseau from Genentech

Covance plans job cuts and lab shutdown from stagnant Q1 performance

George Clinical buys up CRO unit from Vector Oncology, boosting its ops

LivaNova snaps up Minnesota’s Caisson for $72M

Pricing furor aside, drug spending growth slowed last year—but still hit $323B

Featured Story

Swiss majors Roche and Novartis back gene therapy upstart

Thursday, May 4, 2017

Newly born European biotech Vivet Therapeutics has started life with €37.5 million ($41 million) and an executive team made up of Novartis, Sanofi and Gensight veterans, as the company looks to get to work on its gene therapies for a host of rare diseases.

This week's sponsor is Sensors Expo & Conference 2017.

Novartis adds to NASH pipeline, activating license for Conatus' emricasan

Thursday, May 4, 2017

Novartis has bolstered its R&D portfolio for NASH, a progressive fatty liver disease tipped to become a $20 billion to $35 billion market in the coming years, with its second deal in a month.

Poxel shares jump 40% after diabetes trial hits primary goal

Thursday, May 4, 2017

A phase 2b trial of Poxel’s Type 2 diabetes candidate imeglimin has met its primary endpoint. The data sent shares in Poxel soaring 40% and set the company up to push into a phase 3 trial before the end of the year.

[Sponsored] Mitotech’s SkQ1 targets mtROS, and a long list of age-related diseases

Monday, April 24, 2017

It’s a critical tradeoff for life. Our bodies use sugar and fat from the food we consume to produce energy in our cells’ mitochondria, the internal powerhouses that give us the energy we need for all our vital functions.

I-O startup Gritstone lures Rousseau from Genentech

Thursday, May 4, 2017

Gritstone Oncology has appointed Raphaël Rousseau, M.D., Ph.D., as its CMO. Rousseau joins Gritstone from Genentech, becoming the latest biopharma veteran to join the ranks at the well-financed personalized cancer immunotherapy startup.

Covance plans job cuts and lab shutdown from stagnant Q1 performance

Wednesday, May 3, 2017

LabCorp is planning a rejig of its CRO business Covance, and the short-term plan includes letting go of a lab along with the employees stationed there.

George Clinical buys up CRO unit from Vector Oncology, boosting its operations

Thursday, May 4, 2017

Asia-Pacific CRO George Clinical has topped up its cancer services and boosted its U.S. presence after acquiring Memphis, Tennessee-based Vector Oncology's CRO division.

LivaNova snaps up Minnesota’s Caisson for $72M

Wednesday, May 3, 2017

LivaNova, which specializes in neuromodulation, cardiac surgery and rhythm management, will acquire Caisson Interventional, a Minnesota-based heart valve maker, for $72 million.

Pricing furor aside, drug spending growth slowed last year—but still hit $323B

Thursday, May 4, 2017

Despite what you may have heard about drug pricing and expenses getting out of hand, net spending growth actually fell in the U.S. last year. After discounts, pharmaceutical spending increased 4.8% in 2016, down from the 8.9% growth recorded in 2015.

This week's sponsor is J.P. Morgan Private Bank.
	How Pre-Transaction Planning Can Maximize Your Wealth You've worked hard to build a successful healthcare business. To reap the rewards of a sale, merger, recap or IPO, be sure you maximize the value of your equity interests with careful pre-transaction planning. Learn how J.P. Morgan Private Bank can help you protect your wealth. Read the article.

News of Note

Regeneron's R&D costs were $507 million in the first quarter compared to $470 million a year ago, with the extra cash going on development work for fasinumab and REGN2810. Regeneron's financials

Rare disease biotech Rhythm has started a phase 3 test for setmelanotide, its first-in-class melanocortin-4 receptor, for an an ultrarare genetic disorder associated with severe, early-onset obesity and unrelenting appetite. Release

Former CDR Therapeutics and Xcyte Therapies executive Che-Leung Law, Ph.D., has become the new VP of translational medicine at T-cell biotech Harpoon. Statement

Resources

[Whitepaper] Monitoring Risk for ICH GCP Compliance

Presented By: Covance

The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting.

[Whitepaper] Run the Trial You Want with Modern EDC

[Whitepaper] Solving the Knowledge Management Puzzle in Biopharma

[Whitepaper] Immuno-Oncology and the Role of Biomarkers, Companion and Complementary Diagnostics

Presented By: Covance

The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper.